This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MRUS Merus (MRUS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Merus Stock (NASDAQ:MRUS) Get Merus alerts:Sign Up Key Stats Today's Range$87.14▼$96.8650-Day Range$90.00▼$97.0152-Week Range$37.92▼$97.14Volume2.73 million shsAverage Volume1.51 million shsMarket Capitalization$6.83 billionP/E RatioN/ADividend YieldN/APrice Target$95.93Consensus RatingHold Company Overview Merus NV is a clinical-stage immuno-oncology company focused on the discovery and development of bispecific antibody therapeutics for the treatment of cancer. Utilizing its proprietary Biclonics® platform, Merus engineers fully human bispecific antibodies designed to engage immune cells and tumor targets simultaneously. The company’s research efforts are aimed at creating novel therapies with optimized potency, selectivity and safety profiles. The Merus pipeline encompasses multiple Biclonics candidates in various stages of preclinical and clinical development. Key programs are being evaluated in solid tumors and hematological malignancies, with a focus on innovative mechanisms of action that harness T cell redirection, immune checkpoint modulation and co-stimulatory pathways. In addition to its internal development efforts, Merus collaborates with strategic partners to advance select programs and expand its therapeutic reach. Headquartered in Utrecht, the Netherlands, Merus maintains operations in both Europe and the United States, supporting global clinical trials and regulatory activities. The company completed its initial public offering on the Nasdaq stock market in October 2018, and its research sites extend from the Dutch biotech hub to a dedicated U.S. presence in Boston’s ecosystem. Merus is led by a management team with extensive experience in oncology drug development and commercialization. Under the leadership of Chief Executive Officer Ton Logtenberg, the company continues to advance its bispecific antibody platform, aiming to deliver transformative treatments for patients with unmet medical needs.AI Generated. May Contain Errors. Read More Receive MRUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Merus and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MRUS Stock News HeadlinesMRUS Share News TodayJune 2, 2026 | uk.investing.comLeonaBio Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 7, 2026 | globenewswire.comNEW LAW: Congress Approves Setup For Digital Dollar?On July 17th, the House passed the GENIUS Act - and at least one prominent Trump ally is raising alarms. Rep. Marjorie Taylor Greene claims the bill contains 'the entire setup, groundwork and infrastructure to move from cash to digital currency.' If the legislation becomes law, the implications for how Americans store and control their money could be significant. There may be a limited window to act before it takes effect.July 22 at 1:00 AM | Goldco Direct, LLC (Ad)Merus Power Delivers an Energy Storage System for Extreme Arctic ConditionsFebruary 11, 2026 | businesswire.comMerus Completes Genmab Acquisition and Delists From NasdaqDecember 30, 2025 | tipranks.comMerus acquired by Genmab, leadership changes announcedDecember 13, 2025 | msn.comGenmab Completes Acquisition of Merus N.V. to Bolster Oncology PortfolioDecember 12, 2025 | tipranks.comGenmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering PeriodDecember 12, 2025 | businesswire.comSee More Headlines MRUS Stock Analysis - Frequently Asked Questions How were Merus' earnings last quarter? Merus N.V. (NASDAQ:MRUS) announced its quarterly earnings results on Tuesday, August, 5th. The biotechnology company reported ($2.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by $1.06. The biotechnology company had revenue of $8.83 million for the quarter, compared to analysts' expectations of $9.77 million. Merus had a negative trailing twelve-month return on equity of 52.99% and a negative net margin of 673.31%. When did Merus IPO? Merus (MRUS) raised $82 million in an IPO on Thursday, May 19th 2016. The company issued 5,500,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers. What other stocks do shareholders of Merus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Merus investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), e.l.f. Beauty (ELF), Adobe (ADBE), Jabil (JBL) and Disc Medicine (IRON). Company Calendar Last Earnings8/05/2025Today7/22/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MRUS CIK1651311 Webwww.merus.nl Phone(130) 253-8800FaxN/AEmployees37Year Founded2003Price Target and Rating Average Price Target for Merus$95.93 High Price Target$97.00 Low Price Target$90.00 Potential Upside/Downside+6.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($5.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$215.33 million Net Margins-673.31% Pretax Margin-653.35% Return on Equity-52.99% Return on Assets-44.61% Debt Debt-to-Equity RatioN/A Current Ratio7.97 Quick Ratio7.97 Sales & Book Value Annual Sales$36.13 million Price / Sales188.94 Cash FlowN/A Price / Cash FlowN/A Book Value$9.46 per share Price / Book9.51Miscellaneous Outstanding Shares75,850,000Free Float73,041,000Market Cap$6.83 billion OptionableOptionable Beta1.06 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:MRUS) was last updated on 7/22/2026 by MarketBeat.com Staff. From Our PartnersTSM just handed Trump's secretive AI project $100 billionTaiwan Semiconductor just committed another $100 billion to U.S. chip manufacturing - on top of $165 billion a...InvestorPlace | SponsoredMy next big call (under $1)People ask me one question more than any other: "Bryce, if you could only buy ONE coin right now... what would...Crypto 101 Media | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?On July 17th, the House passed the GENIUS Act - and at least one prominent Trump ally is raising alarms. Rep. ...Goldco Direct, LLC | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredElon says “don’t save money.” Is he right?Robert Kiyosaki, author of Rich Dad Poor Dad, says you don't have to wait for Elon Musk's vision of universal ...Freedom Financial | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Merus With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
